MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hope, A. G.
Right arrow Articles by Peters, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hope, A. G.
Right arrow Articles by Peters, J. A.

Vol. 55, Issue 6, 1037-1043, June 1999

Molecular Determinants of (+)-Tubocurarine Binding at Recombinant 5-Hydroxytryptamine3A Receptor Subunits

Anthony G. Hope,1 Delia Belelli, Ian D. Mair, Jeremy J. Lambert, and John A. Peters

Department of Pharmacology and Neuroscience, Ninewells Hospital and Medical School, The University of Dundee, Dundee, United Kingdom

The 5-hydroxytryptamine type 3 (5-HT3) receptor is a transmitter-gated ion channel mediating neuronal excitation. The receptor native to neurons, or as a homopentameric assembly of 5-HT3A receptor subunits, displays a species-dependent pharmacology exemplified by a 1800-fold difference in the potency of (+)-tubocurarine [(+)-Tc] as an antagonist of the current response mediated by mouse and human receptor orthologs. Here, we attempt to identify amino acid residues involved in binding (+)-Tc by use of chimeric and mutant 5-HT3A subunits of mouse and human expressed in Xenopus laevis oocytes. Replacement of the entire extracellular N-terminal domain of the mouse 5-HT3A (m5-HT3A) subunit by that of the human ortholog and vice versa exchanged the differential potency of (+)-Tc, demonstrating the ligand binding site to be contained wholly within this region. Mutagenesis of multiple amino acid residues within a putative binding domain that exchanged nonconserved residues between mouse and human receptors shifted the apparent affinity of (+)-Tc in a reciprocal manner. The magnitude of the shift increased with the number of residues (3, 5, or 7) exchanged, with septuple mutations of m5-HT3A and human 5-HT3A subunits producing a 161-fold decrease and 53-fold increase in the apparent affinity of (+)-Tc, respectively. The effect of point mutations was generally modest, the exception being m5-HT3A D206E, which produced a 9-fold decrease in apparent affinity. We conclude that multiple amino acids within a binding loop of human and mouse 5-HT3A subunits influence the potency of (+)-Tc.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
R. C. Drisdel, D. Sharp, T. Henderson, T. G. Hales, and W. N. Green
High Affinity Binding of Epibatidine to Serotonin Type 3 Receptors
J. Biol. Chem., April 11, 2008; 283(15): 9659 - 9665.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. Yan, J. K. Meyer, and M. M. White
Mapping Residues in the Ligand-Binding Domain of the 5-HT3 Receptor onto d-Tubocurarine Structure
Mol. Pharmacol., August 1, 2006; 70(2): 571 - 578.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Zhang, N. A. White, F. S. Soti, W. R. Kem, and T. K. Machu
N-Terminal Domains in Mouse and Human 5-Hydroxytryptamine3A Receptors Confer Partial Agonist and Antagonist Properties to Benzylidene Analogs of Anabaseine
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1276 - 1284.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. Yan and M. M. White
Spatial Orientation of the Antagonist Granisetron in the Ligand-Binding Site of the 5-HT3 Receptor
Mol. Pharmacol., August 1, 2005; 68(2): 365 - 371.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Schreiter, R. Hovius, M. Costioli, H. Pick, S. Kellenberger, L. Schild, and H. Vogel
Characterization of the Ligand-binding Site of the Serotonin 5-HT3 Receptor: THE ROLE OF GLUTAMATE RESIDUES 97, 224, AND 235
J. Biol. Chem., June 13, 2003; 278(25): 22709 - 22716.
[Abstract] [Full Text] [PDF]

Home page
 Biophys. JHome page
D. C. Reeves, M. F. R. Sayed, P.-L. Chau, K. L. Price, and S. C. R. Lummis
Prediction of 5-HT3 Receptor Agonist-Binding Residues Using Homology Modeling
Biophys. J., April 1, 2003; 84(4): 2338 - 2334.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. K. Machu, M. E. Hamilton, T. F. Frye, C. L. Shanklin, M. C. Harris, H. Sun, T. E. Tenner Jr., F. S. Soti, and W. R. Kem
Benzylidene Analogs of Anabaseine Display Partial Agonist and Antagonist Properties at the Mouse 5-Hydroxytryptamine3A Receptor
J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1112 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
K. T. Min, C. L. Wu, and J. Yang
Nondepolarizing Neuromuscular Blockers Inhibit the Serotonin-Type 3A Receptor Expressed in Xenopus Oocytes
Anesth. Analg., February 1, 2000; 90(2): 476 - 476.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics